French pharmaceutical and healthcare company Sanofi has agreed to buy the British biotechnology firm Vicebio for up to $1.6bn ...

Two recent studies published this week assess the low uptake of respiratory syncytial virus (RSV) vaccine among US veterans and examine the risk factors for intensive care unit (ICU) admission and ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

Vermont has the second lowest state fatality rate in the US (148.4 per 100K; Hawaii 113.7/100K). Mississippi (466/100K) and ...

French pharma giant Sanofi announced on Tuesday that it is to purchase London-based respiratory virus vaccine developer ...

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held ...

Sanofi has moved to bolster its vaccines business by reaching a deal to buy London, UK-based biotech Vicebio, which was ...

Sanofi will gain access to Molecular Clamp technology that enables development of next-generation multivalent vaccines against respiratory pathogens and beyond Lead asset VXB-241 is a bivalent vaccine ...

Paris: Sanofi has announced it has entered into an agreement to acquire Vicebio Ltd, a privately held biotechnology company ...

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held ...

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.